Gubentongluofang To The Treatment Of Stable Angina Pectoirs In Coronary Heart Disease With Type2DM Clinical Research

Objective: To observe the clinical effect of gubentongluofang to the treatment of type2DM with coronary heart disease with stable angina and to investigate its mechanism andthe role of the current progress.: Then select60patients with type2diabetes with coronaryheart disease with stable angina pectoris spleen and kidney deficiency phlegm blockSyndrome, were randomly divided into two groups (A, B),30cases in each group. GroupA for the treatment group taking to Diamicron30mgQD, gubentongluofang. Group B asthe control group, qishenyiqidiwan0.5g Tid, as well as taking the Diamicron30mgQD.The treatment cycle for two months. Results: The total efficacy of TCM symptoms,treatment group, the total effective rate was93.3%, control group, the total effective ratewas70%, the treatment group than the control group (P<0.05), stable angina pectorisefficiency, the treatment group, the total efficiency90%, control group, the total effectiverate was73.3%, the treatment group than the control group (P<0.05),24h dynamicelectrocardiogram indicated the result is that Myocardial oxygen consumption andcoronary artery tension were significantly improved treatment group than the control group(P<0.05).Conclusion: gubentongluofang can significantly improve type2diabetes withcoronary heart disease spleen and kidney deficiency，phlegm blocking the patient’s clinicalsymptoms and some laboratory parameters,and has good clinical effects,can significantlyimprove patient’s quality of life. gubentongluofang for the improvement of coronary heartdisease with type2diabetes patients with stable angina small vessel disease, non-invasivetherapeutic indications of treatment to improve the prevention of stable angina and toprovide new ideas and methods.